Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease entities : Amicus therapeutics, inc. save search
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
Published: 2023-10-02 (Crawled : 01:00) - prnewswire.com
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: -0.66%
H: 0.66%
C: -8.69%
fda disease approval treatment therapeutics
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
Published: 2023-09-28 (Crawled : 15:00) - globenewswire.com
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: -1.32%
H: 1.73%
C: -6.69%
fda disease approval treatment therapeutics
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Published: 2023-08-15 (Crawled : 11:00) - globenewswire.com
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: -2.55%
disease approval therapeutics therapy
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
Published: 2023-06-27 (Crawled : 11:00) - globenewswire.com
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 0.41%
H: 1.57%
C: 0.41%
disease approval therapeutics therapy
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
Published: 2023-04-26 (Crawled : 18:00) - globenewswire.com
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: -0.61%
H: 3.14%
C: 0.7%
opfolda disease chmp positive therapeutics
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
Published: 2023-03-28 (Crawled : 15:00) - biospace.com/
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 0.9%
H: 2.68%
C: 0.27%
disease approval therapeutics
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
Published: 2023-03-27 (Crawled : 13:00) - biospace.com/
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 0.9%
H: 0.27%
C: -1.16%
disease approval therapeutics
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
Published: 2023-02-22 (Crawled : 22:00) - globenewswire.com
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 0.23%
H: 0.11%
C: -0.38%
disease extension therapeutics positive study
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
Published: 2022-12-16 (Crawled : 13:20) - globenewswire.com
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: -0.66%
H: 4.08%
C: 1.83%
disease chmp therapeutics positive
Lysosomal Disease Treatment Market to Reach $14.1 Billion, Globally, by 2031 at 6.4% CAGR: Allied Market Research
Published: 2022-09-06 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: -2.93%
H: 10.14%
C: 3.79%
TAK | News | $13.36 0.91% 0.0% 1.5M
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: -1.11%
NVS | News | $95.12 0.81% 4.36% 160K
|
Health Technology
|
| O: 1.22%
H: 0.46%
C: -1.12%
JNJ | News | $149.12 0.82% 0.59% 440K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.73% 12K
|
Health Technology
|
| O: 0.54%
H: 3.26%
C: 1.28%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -1.35%
H: 0.0%
C: 0.0%
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 0.0%
H: 0.17%
C: -2.36%
treatment research disease market
Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference
Published: 2022-03-16 (Crawled : 11:00) - globenewswire.com
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 1.34%
H: 4.74%
C: 4.74%
pos conference therapeutics disease phase 1 positive
European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease
Published: 2021-12-03 (Crawled : 12:30) - globenewswire.com
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 2.98%
H: 0.0%
C: 0.0%
treatment europe application therapeutics disease
The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
Published: 2021-11-18 (Crawled : 23:00) - biospace.com/
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 0.43%
H: 1.37%
C: -1.89%
disease results phase 3 lancet
U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease
Published: 2021-09-29 (Crawled : 11:00) - biospace.com/
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 10.5%
H: 0.0%
C: -14.13%
disease treatment fda fda acceptance
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
Published: 2021-08-02 (Crawled : 12:00) - biospace.com/
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 0.16%
H: 1.72%
C: 1.29%
disease europe approval
Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases
Published: 2021-05-21 (Crawled : 12:00) - biospace.com/
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: -3.76%
presentation disease
Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 3.76%
H: 2.94%
C: 0.69%
disease treatment fda
Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study
Published: 2021-02-11 (Crawled : 21:03) - globenewswire.com
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: -24.7%
H: 1.74%
C: -10.88%
disease respiratory phase 3
Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021
Published: 2021-02-08 (Crawled : 20:00) - globenewswire.com
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 0.76%
H: 0.7%
C: -3.95%
gene therapy positive therapy disease gene therapies preclinical pre-clinical
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021
Published: 2021-02-08 (Crawled : 20:00) - globenewswire.com
FOLD F | $10.82 1.98% 2.03% 100
|
Health Technology
|
| O: 0.76%
H: 0.7%
C: -3.95%
gene therapy positive therapy disease gene therapies
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | $2.5 100.0% 58.33% 200M
|
Finance
EDBL | News | $6.26 66.49% 48.56% 270K
|
MLEC | $2.47 76.43% 38.05% 460K
|
n/a
PEGY | $0.0458 -10.2% 28.77% 79M
|
Manufacturing
PALI | $4.93 4.67% 25.83% 2.1M
|
Manufacturing
SILO | $1.99 0.71% 20.64% 1.8M
|
Finance and Insurance
NNVC | $1.12 1.82% 19.64% 2.5K
|
Health Technology
CANG | $1.34 -4.29% 14.93% 120K
|
Technology Services
AZTR 4 | $0.195 13.85% 42K
|
n/a
TOVX | News | $0.411 -1.01% 12.9% 230K
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.